Mural Oncology PLC Form 4 insider transactions

Director George Golumbeski of Mural Oncology plc reports the acquisition of stock options on July 30, 2024.

Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology, sold 2,157 shares to cover tax obligations related to vesting restricted stock units.

Caroline Loew, CEO of Mural Oncology plc, sold 12,531 ordinary shares on July 8, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Benjamin Hickey, a director at Mural Oncology plc, filed an amended SEC Form 4 to correct the price of a stock option granted on May 30, 2024.

Francis M. Cuss, a director at Mural Oncology plc, filed an amended SEC Form 4 to correct a scrivener's error regarding the price of a stock option granted on May 30, 2024.

Director Scott Thomas Jackson reports the grant of stock options in Mural Oncology plc, with a subsequent amendment to correct the option price.

Susan Altschuller, a director at Mural Oncology plc, filed an amendment to a previous Form 4 to correct the price of a stock option granted on May 30, 2024.

Director Benjamin Hickey acquired stock options in Mural Oncology plc on May 30, 2024.

Director Francis M. Cuss of Mural Oncology plc reports the acquisition of stock options in the company.

Director Scott Thomas Jackson acquired stock options in Mural Oncology plc on May 30, 2024.

Director Susan Altschuller acquired stock options in Mural Oncology plc on May 30, 2024.

Caroline Loew, CEO of Mural Oncology, files an amended SEC Form 4 to correct a scrivener's error in the reported exercise price of a stock option granted on December 14, 2023.

Caroline Loew, CEO of Mural Oncology plc, reports acquisition of shares and options in the company on March 1, 2024.

Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology, reports acquisition of shares and stock options.